Nektar Therapeutics

Nektar Therapeutics (Nektar) is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California.[3] The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances.[4] It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc.[3] The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.[5]

Nektar Therapeutics
TypePublic
IndustryBiopharmaceuticals
Founded1990
HeadquartersSan Francisco, California, U.S.
ProductsExubera, Movantik[1]
Revenue$1.13 billion (2018)[2]
Number of employees
618 (2018)
Websitenektar.com

Background

The company is engaged in developing a proprietary pipeline of drug candidates for several therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology.[3] The company's research and development involve in small molecule and biologic drug candidates. Its drug candidate base consists of naloxegol (Movantik), a Phase III oral opioid antagonist, etirinotecan pegol, a topoisomerase inhibitor under Phase III clinical study as of 2012, NKTR 061, NKTR-181, NKTR-214, etc.[6]

In 2013, the company was assigned a patent which was developed by the company and other four co-inventors.[7] The products of the company is served as a supplement to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability and other areas of drugs for the patients worldwide.[8] As of March 2014, the company had an market capitalization of $1.7 billion with an enterprise value of $1.67 billion.[2] As of July 15 2019, the company had a market cap of $5.88 Billion.

Pipeline

Etirinotecan pegol was in the phase III BEACON trial, and is in the I-SPY2 adaptive clinical trial for breast cancer.[9]

NKTR-214 is a CD122-biased immune-stimulatory cytokine,[10] Phase I results announced in Nov 2016.[11] It is now in a phase 2 trial in combination with nivolumab for various advanced cancers.[12]

References
  1. "Nektar Therapeutics Profile".
  2. "NKTR Key Statistics | Nektar Therapeutics Inc Stock - Yahoo! Finance". Finance.yahoo.com. Retrieved 2014-03-16.
  3. "BDR: Summary for Nektar Therapeutics, Inc.- Yahoo! Finance". Finance.yahoo.com. Retrieved 2014-03-17.
  4. "Nextar Therapeutics Inc. brief introduction NASDAQ". Nasdaq.com. Retrieved 2014-03-16.
  5. Totty, Michael (2006-09-11). "The Winners Are..." Wall Street Journal. ISSN 0099-9660. Retrieved 2020-01-22.
  6. "NKTR reuter.com". Reuters.com. Retrieved 2014-03-16.
  7. "Nektar Therapeutics : U.S. Patents Awarded to Inventors in Alabama (Feb. 8)". 4-traders.com. 2014-02-08. Retrieved 2014-03-16.
  8. "Nextar Marketwatch Quote Summary". Marketwatch.com. Retrieved 2014-03-16.
  9. Novel Agents are Targeting Drivers of TNBC - Several drug candidates in I-SPY2 have 'graduated' to later-phase studies. 2016
  10. "Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine". Nektar Therapeutics. June 2, 2015. Archived from the original on 19 December 2017. Retrieved 25 June 2015.
  11. Martins, Ines. "Immunotherapy, NKTR-214, Shows Activity Against Solid Tumors in Study". Retrieved 2020-11-12.
  12. "NKTR-214/Nivolumab Combination Shows Promise in Early Study". OncLive. Retrieved 2020-11-12.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.